Uricosuric drugs: the once and future therapy for hyperuricemia?

被引：55

作者：

Bach, Mary H. ^{[1
]}

Simkin, Peter A. ^{[1
]}

机构：

[1] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2014年 / 26卷 / 02期

关键词：

ATP-binding cassette transporter G2; glucose transporter 9; probenecid; URAT1; uricosuric; ORGANIC ANION TRANSPORTERS; URIC-ACID; GOUT; BENZBROMARONE; ALLOPURINOL; PREVALENCE; EXCRETION; GENETICS;

D O I：

10.1097/BOR.0000000000000035

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of reviewAlthough uricosuric agents provide the most time-honoured approach to the control of hyperuricemia, their place in the armamentarium has been eclipsed by that of xanthine oxidase inhibitors. This review considers the potential for uricosuric agents from the perspective of recent progress in the understanding of urate transport systems.Recent findingsNo new agents have yet become available, but promising new drugs are under development. Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia.SummaryConceptually, modest inhibition of renal tubular reabsorption should provide effective relief for the millions of individuals who are now hyperuricemic and who suffer from its principal consequence, gout.

引用

页码：169 / 175

页数：7

共 41 条

[1]

Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans [J].

Anzai, Naohiko ;

Ichida, Kimiyoshi ;

Jutabha, Promsuk ;

Kimura, Toru ;

Babu, Ellappan ;

Jin, Chun Ji ;

Srivastava, Sunena ;

Kitamura, Kenichiro ;

Hisatome, Ichiro ;

Endou, Hitoshi ;

Sakurai, Hiroyuki .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (40) :26834-26838

[2]

Mutations in the SLC2A9 Gene Cause Hyperuricosuria and Hyperuricemia in the Dog [J].

Bannasch, Danika ;

Safra, Noa ;

Young, Amy ;

Karmi, Nili ;

Schaible, R. S. ;

Ling, G. V. .

PLOS GENETICS, 2008, 4 (11)

[3]

Renal Transport of Uric Acid: Evolving Concepts and Uncertainties [J].

Bobulescu, Alexandru ;

Moe, Orson W. .

ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (06) :358-371

[4]

Molybdenum and tungsten enzymes: the xanthine oxidase family [J].

Brondino, CD ;

Romao, MJ ;

Moura, I ;

Moura, JJG .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2006, 10 (02) :109-114

[5]

Drug transport by Organic Anion Transporters (OATs) [J].

Burckhardt, Gerhard .

PHARMACOLOGY & THERAPEUTICS, 2012, 136 (01) :106-130

[6]

Gout therapeutics: new drugs for an old disease [J].

Burns, Christopher M. ;

Wortmann, Robert L. .

LANCET, 2011, 377 (9760) :165-177

[7]

New Therapies for Gout [J].

Crittenden, Daria B. ;

Pillinger, Michael H. .

ANNUAL REVIEW OF MEDICINE, VOL 64, 2013, 64 :325-337

[8]

Molecular identification of a renal urate-anion exchanger that regulates blood urate levels [J].

Enomoto, A ;

Kimura, H ;

Chairoungdua, A ;

Shigeta, Y ;

Jutabha, P ;

Cha, SH ;

Hosoyamada, M ;

Takeda, M ;

Sekine, T ;

Igarashi, T ;

Matsuo, H ;

Kikuchi, Y ;

Oda, T ;

Ichida, K ;

Hosoya, T ;

Shimokata, K ;

Niwa, T ;

Kanai, Y ;

Endou, H .

NATURE, 2002, 417 (6887) :447-452

[9]

Fleischman RM, 2011, ANN RHEUM DIS S3, V70, P188

[10]

Uric acid: A marker of increased cardiovascular risk [J].

Gagliardi, Ana C. M. ;

Miname, Marcio H. ;

Santos, Raul D. .

ATHEROSCLEROSIS, 2009, 202 (01) :11-17

← 1 2 3 4 5 →